Speeded Anomia Treatment in Chronic Post-stroke Aphasia

Sponsor
University of Cambridge (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05512884
Collaborator
Cambridge University Hospitals NHS Foundation Trust (Other)
100
2
12

Study Details

Study Description

Brief Summary

The main aim of the study is to investigate the effect of a novel, speeded anomia therapy (Conroy et al., 2018) in a large population of patients with chronic post-stroke aphasia. The treatment will be delivered via a web application (QuickWord).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Speeded anomia therapy
N/A

Detailed Description

The main aim is to test the clinical efficacy of a novel, web based, rehabilitation approach to aphasic word-finding difficulties (QuickWord). In an initial development and case-series evaluation, Conroy et al (2018, Brain) found that training for both speed as well as accuracy of naming generated much better outcomes to picture naming accuracy and also augmented the carry-over to connected speech production.

This is a randomised, crossover, clinical trial of QuickWord in a group of aphasic patients in the chronic post-stroke period. The comparison will be standard care. The main outcome measures are clinically relevant improvement in naming to confrontation, and spontaneous use of the target vocabulary in a connected speech sample (detailed picture description). Secondary outcome includes measured use of the vocabulary in a story-telling, connected speech assessment (retelling of the Cinderella story).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Testing the Effect of Speeded Anomia Therapy in Patients With Chronic Post-stroke Aphasia: a Cross-over Randomized Controlled Trial
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Speeded anomia therapy

21h of anomia therapy

Behavioral: Speeded anomia therapy
The speeded anomia therapy was introduced as RISP (Repeated, Increasingly Speeded Production) by Conroy et al. (2018). Participants are asked to name the picture presented to them before an auditory stimulus ('beep' sound) at the end of item presentation. In each session the allotted response time is gradually reduced. After an incorrect response, participants are asked to repeat the word three times.

No Intervention: Standard care

Participants' typical daily routine

Outcome Measures

Primary Outcome Measures

  1. Speeded anomia therapy effect in reaction time [Measured over 10 weeks (Week 0, Week 2, Week 4, Week 6, Week 10)]

    Improvement in reaction time in single-item picture naming

  2. Speeded anomia therapy effect in accuracy [Measured over 10 weeks (Week 0, Week 2, Week 4, Week 6, Week 10)]

    Improvement in accuracy in single-item picture naming

  3. Generalisation to connected speech [Measured over 10 weeks (Week 0, Week 2, Week 4, Week 6, Week 10)]

    Improvement in word retrieval in composite picture description. Participants will be asked to describe composite pictures (from the "Where's Waldo/Wally?" publications).

Secondary Outcome Measures

  1. Generalisation to story-telling connected speech [Measured over 10 weeks (Week 0, Week 2, Week 4, Week 6, Week 10)]

    Improvement in narrative speech production. Participants will be asked to narrate the Cinderella story. A checklist with some of the most frequently used nouns (data obtained from AphasiaBank database) will be used.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Native English speakers

  • Age 18 years or above

  • Stroke (any type) greater than 12 months post onset

  • No history of neurological disorders / psychiatric disorders

  • Normal or corrected-to-normal hearing & vision

  • Able to give informed consent

  • Currently not receiving Speech & Language therapy

  • Minimal repetition skills (>40% on an immediate word repetition test)

  • Evidence of naming difficulties (<90% in Boston Naming Test - Goodglass et al., 1983)

Exclusion Criteria:
  • Non-native English speakers

  • Less than 18 years old

  • Stroke less than 12 months post onset

  • History of neurological disorders / psychiatric disorders

  • Uncorrected hearing & vision

  • Unable to give informed consent

  • Currently receiving Speech & Language therapy

  • Insufficient repetition skills (<40% on an immediate word repetition test)

  • Good naming performance (>90% in Boston Naming Test - Goodglass et al., 1983)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Cambridge
  • Cambridge University Hospitals NHS Foundation Trust

Investigators

  • Principal Investigator: Matthew Lambon Ralph, DPhil, MRC Cognition and Brain Sciences Unit, University of Cambridge

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Matthew A. Lambon Ralph, Professor, University of Cambridge
ClinicalTrials.gov Identifier:
NCT05512884
Other Study ID Numbers:
  • 01/8/094
First Posted:
Aug 23, 2022
Last Update Posted:
Aug 23, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Matthew A. Lambon Ralph, Professor, University of Cambridge
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2022